LeonaBio, Inc. (LONA) shareholders
Close on Nov 18, 2026Market cap $24.97MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Portman David J. Joint filing with Sermonix Pharmaceuticals, Inc. (25.10%) | 3,149,470 | 25.10% | 13D (active) amendment | Oct 26, 2026 |
| Leonard Braden Michael Joint filing with BML Investment Partners, L.P. (5.80%) | 2,484,445 | 6.50% | 13G (passive) amendment | Dec 31, 2024 |
| Steven Michael Oliveira | 1,994,649 | 5.11% | 13G (passive) | Apr 14, 2025 |
| Joseph Edelman Joint filing with Perceptive Advisors LLC (19.99%), Perceptive Life Sciences Master Fund, Ltd. (16.50%) | 1,889,403 | 19.99% | 13D (active) amendment | Aug 22, 2026 |
| Perceptive Advisors LLC Joint filing with Joseph Edelman (19.99%), Perceptive Life Sciences Master Fund, Ltd. (16.50%) | 1,889,403 | 19.99% | 13D (active) amendment | Oct 26, 2026 |
| Anders Hove Joint filing with Acorn Bioventures 2, L.P. (7.00%), Acorn Capital Advisors GP 2, LLC (7.00%) and 2 more | 1,492,521 | 12.10% | 13G (passive) amendment | Aug 18, 2026 |
| ADAR1 Capital Management, LLC Joint filing with Daniel Schneeberger (7.70%) | 727,481 | 7.70% | 13G (passive) | Mar 31, 2026 |
| Dr. Jeffrey R. Jay, M.D. Joint filing with Great Point Partners, LLC (5.03%), Ms. Lillian Nordahl (5.03%) | 474,345 | 5.03% | 13G (passive) | Oct 28, 2026 |
| Baselake Partners, LP Joint filing with Baselake Management, LLC (5.00%), David Paolella (5.00%) | 197,481 | 5.00% | 13G (passive) | Nov 7, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of LONA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Perceptive Advisors LLC | 1,859,322 | 19.73% | $17.09M | – | 0.26% |
| Kalehua Capital Management LLC | 787,402 | 8.36% | $7.24M | – | 2.31% |
| ADAR1 Capital Management, LLC | 777,100 | 8.25% | $7.14M | +49,619 | 0.33% |
| Acorn Capital Advisors, LLC | 634,539 | 6.73% | $5.83M | – | 1.59% |
| TCG Crossover Management, LLC | 464,398 | 4.93% | $4.27M | – | 0.10% |
| NEA Management Company, LLC | 464,398 | 4.93% | $4.27M | – | 0.27% |
| Commodore Capital LP | 464,398 | 4.93% | $4.27M | – | 0.25% |
| Spruce Street Capital LP | 393,701 | 4.18% | $3.62M | – | 0.71% |
| Blackstone Inc. | 324,638 | 3.45% | $2.98M | New | 0.01% |
| Adage Capital Partners Gp, L.L.C. | 300,000 | 3.18% | $2.76M | New | 0.00% |
| Vanguard Capital Management LLC | 275,233 | 2.92% | $2.53M | +80,473 | 0.00% |
| Seven Fleet Capital Management LP | 154,153 | 1.64% | $1.42M | −10,523 | 0.23% |
| Propel Bio Management, LLC | 149,279 | 1.58% | $1.37M | – | 0.72% |
| Simplify Asset Management Inc. | 149,279 | 1.58% | $1.37M | – | 0.02% |
| Geode Capital Management, LLC | 80,418 | 0.85% | $739.51K | +95 | 0.00% |
| BlackRock, Inc. | 79,186 | 0.84% | $727.72K | +23,135 | 0.00% |
| Renaissance Technologies LLC | 77,424 | 0.82% | $711.53K | +13,202 | 0.00% |
| Vanguard Fiduciary Trust Co | 42,814 | 0.45% | $393.46K | +2,775 | 0.00% |
| Bank Of America Corp /De/ | 32,557 | 0.35% | $299.20K | −9 | 0.00% |
| Millennium Management LLC | 32,450 | 0.34% | $298.22K | +772 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 44 | 8M | 81.4% | 8 / 8 | 7 / 3 | 1M | 0M |
| Q1 2026 | 40 | 7M | 72.7% | 6 / 12 | 6 / 6 | 1M | 0M |
| Q4 2025 | 42 | 6M | 65.9% | 15 / 8 | 6 / 7 | 5M | 0M |
| Q3 2025 | 34 | 2M | 18.2% | 34 / 0 | 0 / 0 | 2M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
14 funds held LONA in Q2 2026, 85% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of LONA | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 183,259 | 1.95% | $1.68M | 0.00% | Jun 30, 2026 |
| Simplify Propel Opportunities ETF | 149,279 | 1.58% | $1.37M | 1.78% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 82,390 | 0.87% | $757.16K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 35,908 | 0.38% | $342.56K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 21,744 | 0.23% | $199.83K | 0.01% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 11,846 | 0.13% | $113.01K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 10,008 | 0.11% | $95.48K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 6,278 | 0.07% | $59.89K | 0.00% | May 31, 2026 |
| Vanguard Institutional Total Stock Market Index Fund | 5,988 | 0.06% | $55.03K | 0.00% | Jun 30, 2026 |
| U.S. Micro Cap Portfolio | 3,774 | 0.04% | $26.64K | 0.00% | Jul 31, 2026 |
| Vanguard Balanced Index Fund | 3,596 | 0.04% | $33.05K | 0.00% | Jun 30, 2026 |
| Dimensional US Core Equity 1 ETF | 2,614 | 0.03% | $18.45K | 0.00% | Jul 31, 2026 |
| U.S. Vector Equity Portfolio | 1,530 | 0.02% | $10.80K | 0.00% | Jul 31, 2026 |
| 1290 VT Micro Cap Portfolio | 1,416 | 0.02% | $13.01K | 0.01% | Jun 30, 2026 |
| U.S. Social Core Equity 2 Portfolio | 1,253 | 0.01% | $8.85K | 0.00% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Mark James Litton | PRESIDENT and CEO, Director | 59,894 | 0.64% | Apr 13, 2026 |
| Robert Renninger | CHIEF FINANCIAL OFFICER | 15,851 | 0.17% | Apr 13, 2026 |
| Mark Worthington | GENERAL COUNSEL and CCO | 18,376 | 0.20% | Apr 13, 2026 |
| Martin Javier San | CHIEF MEDICAL OFFICER | 15,887 | 0.17% | Apr 13, 2026 |
| Kevin Church | CHIEF SCIENTIFIC OFFICER | 25,178 | 0.27% | Apr 13, 2026 |
| Life Sciences Master Fund Ltd Perceptive | Director, 10% owner | 3,114,805 | 33.06% | Oct 26, 2026 |
| Advisors Llc Perceptive | Director, 10% owner | 776,648 | 8.24% | Oct 26, 2026 |
| Joseph Edelman | Director, 10% owner | 5,402,964 | 57.35% | Oct 26, 2026 |
| Natalie C. Holles | Director | – | – | Jun 24, 2026 |
| Grant Pickering | Director | 25,783 | 0.27% | Jun 24, 2026 |
| Michael A. Panzara | Director | 0 | – | Jun 24, 2026 |
| Kelly A. Romano | Director | 80,715 | 0.86% | Jun 24, 2026 |
| James A. Johnson | Director | 5,000 | 0.05% | Jun 24, 2026 |
| Barbara Kosacz | Director | 0 | – | Jun 24, 2026 |
| Fred Callori | Director | – | – | Jun 24, 2026 |
| Peter B. Silverman | Director | – | – | Jun 24, 2026 |
| John M. Fluke Jr | Director | 148,615 | 1.58% | Apr 13, 2026 |
| Perceptive Xontogeny Venture Fund II, LP | Director, 10% owner | – | – | Dec 23, 2025 |
| David J. Portman | 10% owner | 3,149,470 | 33.43% | Oct 28, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| David J. Portman 10% owner | Oct 26, 2026 | Buy | +3,149,470 | $3149.47 | $9.92B | 3,149,470 |
| Advisors Llc Perceptive Director, 10% owner | Oct 26, 2026 | Option exercise | +776,648 | $0.00 | $777 | 776,648 |
| Robert Renninger CHIEF FINANCIAL OFFICER | Mar 4, 2026 | Sale | −906 | $5.37 | $4.87K | 15,851 |
| Kevin Church CHIEF SCIENTIFIC OFFICER | Mar 4, 2026 | Sale | −1,359 | $5.37 | $7.30K | 25,178 |
| Mark Worthington GENERAL COUNSEL and CCO | Mar 4, 2026 | Sale | −1,328 | $5.37 | $7.13K | 18,376 |
| Martin Javier San CHIEF MEDICAL OFFICER | Mar 4, 2026 | Sale | −1,720 | $5.37 | $9.24K | 15,887 |
| Mark James Litton PRESIDENT and CEO, Director | Mar 4, 2026 | Sale | −5,156 | $5.37 | $27.69K | 57,926 |
| Robert Renninger CHIEF FINANCIAL OFFICER | Mar 3, 2026 | Option exercise | +3,900 | – | – | 16,757 |
| Kevin Church CHIEF SCIENTIFIC OFFICER | Mar 3, 2026 | Option exercise | +5,856 | – | – | 26,537 |
| Mark Worthington GENERAL COUNSEL and CCO | Mar 3, 2026 | Option exercise | +5,726 | – | – | 19,704 |
| Martin Javier San CHIEF MEDICAL OFFICER | Mar 3, 2026 | Option exercise | +7,418 | – | – | 17,607 |
| Mark James Litton PRESIDENT and CEO, Director | Mar 3, 2026 | Option exercise | +22,254 | – | – | 63,082 |
| Martin Javier San CHIEF MEDICAL OFFICER | Jan 2, 2026 | Sale | −1,644 | $6.88 | $11.31K | 10,189 |
| Mark Worthington General Counsel and CCO | Jan 2, 2026 | Sale | −876 | $6.88 | $6.03K | 13,978 |
| Kevin Church CHIEF SCIENTIFIC OFFICER | Jan 2, 2026 | Sale | −876 | $6.88 | $6.03K | 20,681 |
| Mark James Litton President and CEO, Director | Jan 2, 2026 | Sale | −2,586 | $6.88 | $17.79K | 40,828 |
| Robert Renninger Chief Financial Officer | Jan 2, 2026 | Sale | −297 | $6.88 | $2.04K | 12,857 |
| Martin Javier San CHIEF MEDICAL OFFICER | Dec 31, 2025 | Option exercise | +4,667 | – | – | 11,833 |
| Mark Worthington General Counsel and CCO | Dec 31, 2025 | Option exercise | +3,667 | – | – | 14,854 |
| Kevin Church CHIEF SCIENTIFIC OFFICER | Dec 31, 2025 | Option exercise | +3,667 | – | – | 21,557 |
| Mark James Litton President and CEO, Director | Dec 31, 2025 | Option exercise | +10,834 | – | – | 43,414 |
| Robert Renninger Chief Financial Officer | Dec 31, 2025 | Option exercise | +1,236 | – | – | 13,154 |
| Advisors Llc Perceptive Director, 10% owner | Dec 23, 2025 | Award | +329,756 | $6.35 | $2.09M | 329,756 |
| Advisors Llc Perceptive Director, 10% owner | Dec 23, 2025 | Award | +989,270 | $6.35 | $6.28M | 1,529,566 |
| Kevin Church CHIEF SCIENTIFIC OFFICER | Nov 18, 2025 | Award | +1,000 | $2.31 | $2.31K | 17,890 |
| Robert Renninger Chief Financial Officer | Nov 18, 2025 | Award | +1,000 | $2.31 | $2.31K | 11,918 |
| Martin Javier San CHIEF MEDICAL OFFICER | Jul 1, 2025 | Sale | −10,842 | $0.29 | $3.14K | 71,665 |
| Mark James Litton President and CEO, Director | Jul 1, 2025 | Sale | −25,123 | $0.29 | $7.29K | 325,802 |
| Mark Worthington General Counsel and CCO | Jul 1, 2025 | Sale | −8,526 | $0.29 | $2.47K | 111,875 |
| Kevin Church CHIEF SCIENTIFIC OFFICER | Jul 1, 2025 | Sale | −8,526 | $0.29 | $2.47K | 168,901 |
| Robert Renninger SVP, Finance and Accounting | Jul 1, 2025 | Sale | −2,897 | $0.29 | $840 | 109,186 |
| Martin Javier San CHIEF MEDICAL OFFICER | Jun 30, 2025 | Option exercise | +46,666 | – | – | 82,507 |
| Mark James Litton President and CEO, Director | Jun 30, 2025 | Option exercise | +108,334 | – | – | 350,925 |
| Mark Worthington General Counsel and CCO | Jun 30, 2025 | Option exercise | +36,666 | – | – | 120,401 |
| Kevin Church CHIEF SCIENTIFIC OFFICER | Jun 30, 2025 | Option exercise | +36,666 | – | – | 177,427 |
| Robert Renninger SVP, Finance and Accounting | Jun 30, 2025 | Option exercise | +12,359 | – | – | 112,083 |
| Kevin Church CHIEF SCIENTIFIC OFFICER | May 19, 2025 | Award | +10,000 | $0.23 | $2.30K | 140,761 |
| Robert Renninger SVP, Finance and Accounting | May 19, 2025 | Award | +10,000 | $0.23 | $2.30K | 99,724 |
| Martin Javier San CHIEF MEDICAL OFFICER | Jan 2, 2025 | Sale | −10,826 | $0.56 | $6.06K | 35,841 |
| Kevin Church CHIEF SCIENTIFIC OFFICER | Jan 2, 2025 | Sale | −8,510 | $0.56 | $4.77K | 130,761 |
| Robert Renninger VP of Finance | Jan 2, 2025 | Sale | −2,881 | $0.56 | $1.61K | 89,724 |
| Mark James Litton President and CEO, Director | Jan 2, 2025 | Sale | −25,107 | $0.56 | $14.06K | 242,591 |
| Mark Worthington General Counsel and CCO | Jan 2, 2025 | Sale | −8,510 | $0.56 | $4.77K | 83,735 |
| Martin Javier San CHIEF MEDICAL OFFICER | Dec 31, 2024 | Option exercise | +46,667 | – | – | 46,667 |
| Kevin Church CHIEF SCIENTIFIC OFFICER | Dec 31, 2024 | Option exercise | +36,667 | – | – | 139,271 |
| Robert Renninger VP of Finance | Dec 31, 2024 | Option exercise | +12,359 | – | – | 92,605 |
| Mark James Litton President and CEO, Director | Dec 31, 2024 | Option exercise | +108,333 | – | – | 267,698 |
| Mark Worthington General Counsel and CCO | Dec 31, 2024 | Option exercise | +36,667 | – | – | 92,245 |
| Kevin Church CHIEF SCIENTIFIC OFFICER | Nov 18, 2024 | Award | +9,920 | $0.55 | $5.46K | 102,604 |
| Robert Renninger VP of Finance | Nov 18, 2024 | Award | +3,651 | $0.55 | $2.01K | 80,246 |
| Mark Worthington General Counsel and CCO | Nov 18, 2024 | Award | +3,651 | $0.55 | $2.01K | 55,578 |
| Mark Worthington GENERAL COUNSEL | Sep 5, 2024 | Sale | −2,525 | $0.57 | $1.44K | 51,927 |
| Kevin Church CHIEF SCIENTIFIC OFFICER | Sep 5, 2024 | Sale | −2,525 | $0.57 | $1.44K | 92,684 |
| Rachel Lenington COO and CDO | Sep 5, 2024 | Sale | −2,525 | $0.57 | $1.44K | 20,870 |
| Mark James Litton President and CEO, Director | Sep 5, 2024 | Sale | −5,032 | $0.57 | $2.87K | 159,365 |
| Andrew Gengos CFO and Chief Business Officer | Sep 5, 2024 | Sale | −1,272 | $0.57 | $725 | 97,532 |
| Mark Worthington GENERAL COUNSEL | Sep 3, 2024 | Award | +10,000 | – | – | 54,452 |
| Kevin Church CHIEF SCIENTIFIC OFFICER | Sep 3, 2024 | Award | +10,000 | – | – | 95,209 |
| Rachel Lenington COO and CDO | Sep 3, 2024 | Award | +10,000 | – | – | 23,395 |
| Mark James Litton President and CEO, Director | Sep 3, 2024 | Award | +20,000 | – | – | 164,397 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 10 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of LeonaBio's stock actually held short. Settlement fails (shares not delivered on time) peaked at 43,327 shares on Oct 2, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Mark James Litton Officer, Director | Mar 4, 2026 | 5,156 | $27.66K | Mar 4, 2026 | Restricted Stock Lapse - See Remarks |
| Mark Worthington Officer | Jul 1, 2025 | 8,526 | $2.50K | Jul 1, 2025 | Restricted Stock Lapse - See Remarks |
| Mark James Litton Officer, Director | Jul 1, 2025 | 25,123 | $7.37K | Jul 1, 2025 | Restricted Stock Lapse - See Remarks |
| Kevin Church Officer | Jul 1, 2025 | 8,526 | $2.50K | Jul 1, 2025 | Restricted Stock Lapse - See Remarks |
| Martin Javier San Officer | Jul 1, 2025 | 10,842 | $3.18K | Jul 1, 2025 | Restricted Stock Lapse - See Remarks |
| Kevin Church Officer | Jan 2, 2025 | 8,510 | $4.78K | Jan 2, 2025 | Restricted Stock Lapse - See Remarks |
| Martin Javier San Officer | Jan 2, 2025 | 10,826 | $6.08K | Jan 2, 2025 | Restricted Stock Lapse - See Remarks |
| Mark James Litton Officer, Director | Jan 2, 2025 | 25,107 | $14.11K | Jan 2, 2025 | Restricted Stock Lapse - See Remarks |
| Mark Worthington Officer | Jan 2, 2025 | 8,510 | $4.78K | Jan 2, 2025 | Restricted Stock Lapse - See Remarks |
| Mark James Litton Officer, Director | Sep 5, 2024 | 5,032 | $1 | Sep 5, 2024 | Restricted Stock Lapse - See Remarks |
Congress trades
3 trades in LeonaBio reported by 1 member of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| Christopher L. Jacobs NY27 | Bought | Dec 12, 2022 | $1K–15K | Jan 20, 2023 |
| Christopher L. Jacobs NY27 | Sold | Nov 8, 2022 | $1K–15K | Dec 12, 2022 |
| Christopher L. Jacobs NY27 | Bought | Jul 18, 2022 | $1K–15K | Sep 9, 2022 53 days late |
See a number that looks wrong?